Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumors

Completed · Phase 1

Conditions studied: Neoplasms

In brief

The primary purpose of this study is to study the side effects of PF-00299804 and determine the highest dose that can be safely administered in patients with advanced cancer.

Key facts

Study ID

NCT00225121

Run by

Pfizer

People needed

121

Starts

2005-10-11

Expected to finish

2010-09-23

Last updated by the study team

2018-12-21

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Malignant solid tumor for which there is no currently approved treatment
• Adequate bone marrow, liver, cardiac, and kidney function

You may not qualify if…

• Cardiac disease
• Anticancer therapy within 4-6 weeks (depending on therapy)
• Pregnant or breast-feeding

Where it is running

• Ronald Reagan UCLA Medical Center — Los Angeles, California, United States
• UCLA Hematology/Oncology — Los Angeles, California, United States
• UCLA Oncology Center — Los Angeles, California, United States
• UCLA Hematology Oncology - Santa Monica — Santa Monica, California, United States
• UCLA Santa Monica Hematology/Oncology — Santa Monica, California, United States
• University of Colorado Hospital — Aurora, Colorado, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• Vereniging het Nederlandse Kanker Instituut — Amsterdam, Netherlands

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.